Paul A. DeRidder, M.D., MBA

Our main business is not to see what lies dimly at a distance but to do what lies clearly at hand.
Thomas Carlyle (1795-1881)
China Market Assistance
Home Page
Biography
Biography-Mandarin
Curriculum Vitae
Resume
AsianAssocPresent
China_Angels
Chinese_Party_2007
Invite_XiJinjingForum
SABPA_ThirdAnnual08
SFDA_Regulatory
TCA_recognition_06
Numira_Biosciences_press
Laughter...BestMedicine
TsinghuaUEntrepreneur
VC Invest Lifescience
Gen_Engineer_News_Quote
The Scientist-Quote
InVitroDiagnostic_Suzhou
Experience

Facilitated "spin-out" technology from BioSante Pharmaceuticals, Inc. and co-Founded Cold Genesys, Inc.

 LINCOLNSHIRE, Illinois (November 17, 2010) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer.

Cold Genesys, Inc is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment with a present emphasis on bladder cancer. Based in Newport Beach, California, Cold Genesys is a privately funded, early-stage company anticipating global development of its technology.

http://www.forbes.com



Gen-Probe Incorporated (NASDAQ: GPRO) is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) used primarily to diagnose human diseases and screen donated human blood.

October 21, 29008
Provided advisory services in evaluation of the China market in InVitro Diagnostic technology and business practices.  Arranged a two day Summit with Key Government and PRC  Business leaders.
________________________________________________

2005 Co-Founder and assisted in $1.1M Venture Capital Series A Raise

VANDOLAY
Non-Invasive Venous Ligation

Website Builder